Polyethylenimine (PEI), a polycation with high ionic charge density, has recently been used as a gene therapy delivery agent. We have defined the optimal conditions for PEI-based transfection of airway epithelial cells in vitro and in vivo and used these conditions to restore Cl À channel activity in a CF mouse model. Three forms of PEI, a linear 22 kDa (ExGen 500) form and branched 25 or 50 kDa forms were evaluated. All forms of PEI significantly increased luciferase reporter gene expression compared to the liposome DCChol/DOPE in a human bronchial epithelial cell line (16HBE) irrespective of the extent of cell confluency. With subconfluent cells, gene expression was around 1000-, 200-and 25-fold higher than liposomes using linear 22, 25 and 50 kDa PEI, respectively. The transfection efficiency was reduced in confluent and polarized epithelial cells but linear 22 kDa PEI showed the smallest decrease and gave 8000-fold better transfection in polarized cells compared to liposomes. A comparison of linear 22 or 25 kDa PEI with DCChol/DOPE for airway delivery in vivo via intranasal instillation was also performed. Linear 22 kDa PEI gave significantly better luciferase reporter gene expression of 350-fold in the lung, 180-fold in the nose and 85-fold in the trachea compared to liposome. In contrast, the 25 kDa form of PEI was no better than DCChol/ DOPE. Repeat dosing with linear 22 kDa PEI failed to give reporter gene delivery comparable to the initial dose. To establish that PEI can be used to deliver a physiologically relevent gene in vivo, we used it to restore Cl À secretion by CFTR gene delivery in the airways of a CF mouse model.
Introduction
Clinical disorders exhibiting pulmonary pathology, such as cystic fibrosis (CF), 1 are excellent candidates for gene therapy because of the relative ease by which substances can be delivered to the lung. Unfortunately, gene therapy clinical trials for CF using nonviral delivery vehicles have demonstrated limited efficacy. [2] [3] [4] [5] [6] [7] The most commonly used nonviral vectors are cationic lipids, but recently there has been growing interest in non-lipid polycations such as polyethylenimine (PEI). PEI has been used to transfect oligonucleotides and plasmid into cells in vitro and in vivo. 8 Optimization of protocols has resulted in rates of transfection up to four orders of magnitude higher than with naked DNA. 9 PEI binds to DNA by an electrostatic interaction to form small complexes that are internalized into cells by endocytosis and can localize to the nucleus as distinct structures. 10 The high efficiency of PEI as a transfection reagent may be caused by its large buffering capacity, which brings about a change in endosomal osmolarity sufficient to cause lysis. 8, 11 Endosomal release may enhance gene delivery to the nucleus of transfected cells. PEI is available in a range of sizes and structures, including 25 and 50 kDa branched polymers and a 22 kDa linear form (ExGen 500). Linear 22 kDa PEI shows the highest transfection efficiency in several different systems both in vitro and in vivo. 9, 12, 14 PEI has gene delivery properties that have been suggested to make it a suitable nonviral delivery agent for gene therapy of airway disease. 12, 13 PEI has been tested for intravenous delivery of several reporter genes. In general, these studies have shown that linear 22 kDa PEI gives better lung delivery than branched 25 kDa PEI or liposomes but gene expression is mainly restricted to alveolar cells, such as pneumocytes, which are not a suitable target for treatment of CF. 9, 14, [15] [16] [17] In addition, maximum gene delivery to the lung is only achieved after systemic administration under conditions that are starting to cause liver necrosis and death. 18 So intravenous delivery of PEI is probably not the best route for CF treatment. An alternative route of administration is via intratracheal delivery. Although this route has not been as widely studied as intravenous delivery, it has been shown that aerosolization of 25 kDa branched PEI can give CAT gene expression in the lungs and transfect the epitheilal cells of the conducting airways. 19, 20 Similarly Bragonzi et al have shown that both 25 kDa and linear 22 kDa PEI can deliver a luciferase reporter gene to the lungs of mice. 16 PEI has not yet been used to deliver a physiologically relevent gene to the airways. We have compared the ability of three forms of PEI to deliver a reporter gene to a human bronchial epithelial cell line (16HBE) as a model for airway gene delivery under different culture conditions (subconfluent, confluent and polarized). 21, 22 We have shown that all three forms of PEI gave significantly better reporter gene delivery compared to using liposomes. Linear 22 kDa PEI was significantly better than branched 25 or 50 kDa PEI. The linear 22 kDa PEI also gave significantly better gene expression in the lung compared with either 25 kDa PEI or liposomes. However, repeat dosing with linear 22 kDa PEI-DNA failed to give reporter gene delivery comparable to the initial dose. Linear 22 kDa PEI also gave significant reporter gene delivery to the trachea and nasal epithelia and its evaluation for delivery of the CFTR gene to the trachea of null cystic fibrosis mice resulted in correction of the CF defect.
Results

Linear 22 kDa PEI gives the best transfection efficiencies in vitro at all cell densities
We evaluated the efficiency of various types of PEI for reporter gene delivery to the human airway epithelial cell line 16HBE. Cells were grown to different states of confluency and differentiation prior to transfection with the luciferase reporter plasmid pVR1223 complexed with one of three different PEIs; a linear 22 kDa (L-22 kDa), branched 25 kDa (B-25 kDa) or 50 kDa (B-50 kDa) PEI. To provide a comparative reference point, the luciferase plasmid was complexed with the liposome DCChol/ DOPE (lipoplex). On subconfluent 16HBE cells, all forms of PEI gave better gene delivery to levels significantly higher than lipoplex (Figure 1a ). The efficiency of transfection was reduced in confluent ( Figure 1b) and polarized epithelial cells (Figure 1c ) for all the transfection agents but the L-22 kDa PEI was significantly better than the other transfection agents at all cell confluencies tested. The transfection efficiency of the B-25 kDa PEI-DNA complex formulated at an N/P ratio of 5:1 (rather than 10:1, as for all other in vitro experiments) was reduced in all cell confluencies tested, significantly in the case of subconfluent cells (Po0.01). As a result of the low efficiency of B-50 kDa in polarized cells, it was decided that further experiments would compare only L-22 kDa and B-25 kDa PEI.
Linear 22 kDa PEI gives the best transfection efficiency in the mouse airways L-22 kDa, B-25 kDa PEI and DCChol/DOPE lipoplexes were evaluated for luciferase reporter gene delivery to the mouse airways ( Figure 2 ). The L-22 kDa PEI gave consistently higher gene expression than lipoplex in the lungs (30-fold), nose (180-fold) and trachea (15-fold). B-25 kDa PEI gave two-fold higher gene expression than lipoplex in the lung. Luciferase reporter gene delivery to nose and trachea with B-25 kDa failed to exceed background levels (data not shown).
Time course of luciferase expression after airway delivery with 22 kDa PEI or DCChol/DOPE liposomes We examined the time course of luciferase gene expression in the mouse airways after gene delivery with DCChol/DOPE or L-22 kDa PEI (Figure 3 ). In the lung, 
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DCChol/DOPE showed highest luciferase gene expression at 6 h post-transfection, decreasing by around 50% at 48 h. Delivery to the nasal epithelium was less reproducible with only one mouse in six at the 6 h and 48 h time points giving activity above background levels.
Expression within the trachea was equivalent to background levels in all mice tested. For comparison, gene expression with lipoplex at 6 h was around 350-fold less than the L-22 kDa PEI. The time course expression profile was markedly different between lipoplex and L-22 kDa PEI. In the lung, L-22 kDa PEI shows its lowest level of expression at 6 h, and this peaked at 18 h. At all time points between 12 and 48 h, the transfection efficiency of L-22 kDa PEI is significantly higher than lipoplex in the Effect of re-dosing mice with linear 22 kDa PEI-DNA complexes on transfection efficiency of the lung
Clinical treatment for pulmonary disease, such as CF by gene replacement will require frequent repeat administrations. To investigate the effect of re-dosing, five groups of mice were transfected with a luciferase reporter gene and three groups killed after 18 h, 4 days or 7 days. The remaining two groups were re-dosed at 7 days and killed 18 h or 4 days after the second transfection. Lungs (Figure 4a ), nasal epithelia ( Figure 4b ) and trachea ( Figure 4c ) from all groups were assayed for luciferase expression. At 18 h after the initial dose, reporter gene expression in the lung was 18 000 RLU (relative light units)/mg protein, which fell to 2500 RLU/mg 4 days post-transfection. By 7 days, reporter gene expression had dropped to 1300 RLU/mg and animals re-dosed at this time point gave only modest luciferase activities (3300 RLU/mg) 18 h later. This was significantly higher than the 7 day initial dose value (Po0.01), but significantly lower (approx. 20%) than the 18 h initial dose value (Po0.01). In the nose and trachea, the drop in expression from 18 h to 7 days after initial dosing was from 94 to 4 RLU/mg and 115 to 0.56 RLU/mg, respectively. In nasal epithelia, there was no increase in reporter gene expression following re-dosing but in the trachea there was a small increase 18 h after re-dosing with the expression level rising from 0.56 to 5.15 RLU/ mg (Po0.05). However 4 days after re-dosing, expression in both nasal epithelia and trachea was back to background levels. Thus, re-dosing mice at 7 days with L-22 kDa PEI/luciferase resulted in lower levels of reporter gene expression than observed after the first dose. Reduced expression after a second dose may be because of a variety of reasons including: antibody production against luciferase, unmethylated CpGs within bacterial DNA sequences in the plasmids causing immune stimulatory effects, 23 or the effect of the anaesthesia/anaesthetic upon the mice.
To investigate whether a humoural response was involved, we transfected a group of six mice with a plasmid encoding b-galactosidase and re-dosed at 7 days with the luciferase reporter plasmid. Mice were killed 18 h after the second transfection (Figure 4d ). Results were similar to those where mice were dosed both initially and at 7 days with the luciferase plasmid with luciferase expression levels after the second dose only reaching around 20% of the first dose value.
We also used BALB/c nude mice, to investigate if Tcell-mediated immune responses were responsible for the reduction of expression upon re-dosing. We transfected three groups of six mice with luciferase reporter plasmid and killed one group at 18 h and another at 7 days post-transfection. The last group was re-dosed at 7 days and killed 18 h after the second transfection ( Figure  4d ). The pattern of results was similar to that seen with normal BALB/c mice with the re-dose value only reaching around 20% of the first dose value.
The effect of extending the time between doses was also examined. Five groups of six mice were transfected with a luciferase reporter plasmid and three groups were analyzed at 18 h, 7 days or 25 days post-transfection. The remaining two groups were re-dosed at 7 days or 25 days and analyzed 18 h later for luciferase assay. Higher expression was obtained following re-dosing after 25 days than after 7 days. The 25 day re-dose gave 49% of the first dose level while the 7 day re-dose only gave approximately 10% of the original level (Figure 4e ).
Delivery of hCFTR cDNA to the airways of CF-null mice using L-22 kDa PEI The treatment of CF by gene replacement therapy will require delivery of CFTR cDNA for correction of the CF defect. We investigated whether linear 22 kDa PEI complexed with a plasmid encoding the human CFTR cDNA (pT10CFTR2) could restore CFTR-dependent chloride (Cl À ) secretion in the trachea of CF-null mice (Cftr tm1Cam ). 24 We used the isoflavone genistein to activate CFTR-mediated Cl À secretion in the murine trachea. 25 In response to genistein, wild-type mice, expressing CFTR, show an increase in Cl À secretion while CF-null mice, which do not produce any functional CFTR protein, show no Cl À secretion. CF-null mice were transfected with L-22 kDa PEI-pT10CFTR2, and four out of nine mice showed Cl À secretion in response to genistein (individual results: 12.9, 10.3, 9.0, 7.7 mAcm , n¼6) ( Figure 5 ). The proportion of mice (4/9) that showed restoration of CFTR activity was similar to the variation in luciferase expression in the trachea after L-22 kDa PEI delivery of the luciferase reporter plasmid (individual tracheal measurements: 233.6, 12.1, 1.5, 22.4, 4.3, 12.6 RLU/mg). The variation in response in the pT10CFTR2-treated animals meant that the average genistein response was not significantly different from the CF mice treated with the control plasmid pT10. If it is assumed, however, that the lack of a genistein response reflects a failure of gene delivery and these 'failures' are excluded, then the mean genistein response after L- 22 
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JW Wiseman et al polarized cells. This may be because of the ability of L-22 kDa PEI to deliver DNA to the nucleus of transfected cells, thus avoiding the need for cell division to facilitate efficient gene delivery. 26 It has been shown that efficient cationic lipid-mediated transfection of cells in culture requires mitotic activity. 27 Linear 22 kDa PEI was consistently better than lipoplex or branched 25 kDa PEI in the lung, trachea and nasal epithelium. Achieving gene expression in the trachea and nasal epithelium with linear PEI was encouraging as lipoplex or branched 25 kDa PEI delivery to these tissues gave values close to the background levels. The relative failure of branched 25 kDa PEI was surprising as previous studies resulted in high levels of GFP expression in bronchial cells. 16 This may be because of tracheal delivery of 2.5-fold more plasmid DNA compared to our intranasal delivery. On comparing linear 22 kDa PEI and lipoplex luciferase delivery to lung tissue at various time points, up to 72 h, we saw significantly better expression using linear 22 kDa PEI at all time points. In the trachea and nasal epithelium, we saw similar results with linear 22 kDa PEI superior to lipoplex with statistically significant differences at some of the time points assessed. However, error bars are large because of the wide ranging expression values that we see in trachea and nasal epithelia within each group of mice.
An important factor in gene delivery to the airways is the ability to perform repeat dosing with no reduction in the level of gene expression. We have shown that a second delivery 7 days after the initial treatment only gives around 20% of the initial gene expression level. This decrease is unlikely to be caused by antibody production against the luciferase protein as it is still observed when the first plasmid encodes an unrelated protein (b-galactosidase), and in nude mice which cannot elicit T-cell-dependent antibody responses. Reduced gene expression after a second dose has been found by others and ascribed to induction of inflammatory cytokines in response to unmethylated CpG motifs in the plasmid DNA. 28 Our observation that luciferase gene expression is found following a second dose 25 days after the first is consistent with this. Decreased gene expression following a second dose may also be because of the toxic side effects associated with PEI, which have been reported following systemic injection of PEI-DNA complexes. 18 The definitive test for a proposed gene therapy delivery vehicle is whether it can be used to obtain expression of a gene of physiological relevance to the clinical disorder. The relative potency of the linear 22 kDa PEI in vivo compared to other forms of PEI or the liposome DCChol/DOPE encouraged us to evaluate whether it could be used to restore Cl À secretion in a null mouse model of CF after delivery of a hCFTR cDNA plasmid. While we obtained electrophysiological correction in around 50% of the CF mice, the other animals showed no indication of gene delivery. The reason for the refractoriness of some animals to gene delivery/expression is not known, but we have observed a similar effect with delivery of hCFTR using DCChol/DOPE (30-40% failure) and the luciferase gene using linear 22 kDa PEI (10-20% failure). It is interesting that although linear 22 kDa PEI is consistently better than DCChol/DOPE for luciferase gene expression in the upper airways (nose and trachea), this does not translate into a more consistent delivery of hCFTR.
A potential difficulty in using linear 22 kDa PEI for CFTR delivery is the effect it has on the electrophysiological responses of the target tissue. Genistein responses in a wild-type trachea are around 26 mA/cm 2 but 12 h after dosing with a linear 22 kDa PEI/plasmid complex this has fallen to around 7 mA/cm 2 . Thus, linear 22 kDa PEI has a detrimental effect on the electrophysiological responses of the treated tissue which must be taken into account in the experimental design. Others have also observed a deterioration in lung function up to 72 h after linear 22 kDa PEI delivery. 29 This may be because of the toxicity of PEI mentioned above. It is ironic that agents that give the highest gene delivery in the airways are those that compromise the normal physiology the most.
This study evaluated different forms of PEI for their ability to deliver a luciferase reporter gene to airway epithelial cells in culture and to mouse airways. Having determined that linear 22 kDa PEI was the most efficient, we looked at delivering both a reporter gene and the CFTR gene to mouse airways using this PEI. Linear 22kDa PEI was highly effective and gave consistently good reporter gene transfection of lung when delivered via the airways. Delivery to the trachea using this PEI was encouraging but inconsistent with large variations in reporter gene expression. Delivery of CFTR cDNA to the trachea with linear 22 kDa PEI showed similar variations in expression but proved successful in approximately 50% of mice tested.
Material and methods
Reagents
Unless stated otherwise reagents were obtained from Sigma-Aldrich Ltd. (Poole, UK). Three formulations of PEI-mediated gene delivery JW Wiseman et al PEI were used in this study: ExGen500, a 22 kDa linear PEI (Euromedex, Souffelweyersheim, France), supplied as an aqueous solution, 10 mM in PEI, 5.47 mM in nitrogen residues. A 25 kDa branched PEI prepared as a stock solution of 0.045 g in 50 ml of 150 mM NaCl (10 mM in nitrogen residues) titrated to pH 7, and 50 kDa branched PEI prepared as a stock solution of 0.09 g in 50 ml of 150 mM NaCl (10 mM in nitrogen residues) titrated to pH 7.
Cell culture
Human bronchial epithelial cells 16HBE 22 (generously provided by Professor Dieter Gruenert, University of Vermont, VT, USA) were grown in minimal essential medium with Earle's salts (Invitrogen, Paisley, UK) supplemented with 10% foetal calf serum (FCS, TCS Biologicals, Buckingham, UK), 2 mM L-glutamine (Invitrogen), 100 U/ml penicillin and streptomycin (Invitrogen). Culture of polarized cells on Anopore membranest (Invitrogen) differed in that the FCS was replaced by 2% Ultroser G (Invitrogen). For subconfluent transfection studies, 16HBE cells were seeded to reach 70% confluency at the time of transfection. For confluent transfection, cells were used 2-3 days after reaching 100% confluency. Differentiated polarized cells were grown in 10 mm diameter tissue culture chambers containing 0.2 mm Anoporet membranes and cultured for at least 10 days postconfluency. Cell polarization was confirmed by measuring the transepithelial electrical resistance of the epithelial cell layer with an EVOM voltmeter (World Precision Instruments FL, USA).
In vitro gene transfer
Cells were seeded in six-well multidishes (Invitrogen) for confluent and subconfluent transfection. Prior to transfection, cells were rinsed sequentially with PBS and Optimem (Invitrogen). Usually 1 mg of the luciferase reporter plasmid pVR1223, 30 (generously provided by Vical Inc. USA) and 5 mg of DCChol/DOPE (generously provided by Professor L Huang, University of Pittsburgh, PA, USA), each diluted in 100 ml of Optimem (Invitrogen), were mixed and incubated at room temperature for 15 min and then added to each well for 2 h at 371C, 5% CO 2. Transfection complex was then removed and the cells were rinsed with PBS. Fresh growth medium was added and the cells were grown for a further 48 h before being assayed for luciferase activity. PEI and plasmid were complexed immediately prior to transfection by firstly diluting PEI and plasmid separately to the required concentration in 150 mM saline; vortexing and leaving at room temperature for 15 min. PEI was then added slowly to the plasmid, and the mixture vortexed and incubated at room temperature for a further 15 min. For in vitro transfections, an N/P ratio of 10:1 was primarily used, yielding positively charged complexes (1 mg DNA is 3 nM of phosphate; 1 ml of 25/ 50 kDa PEI stock solutions contains 10 nM of amine nitrogen; 1 ml ExGen 500 contains 5.47 nM of amine nitrogen). Usually 1 mg plasmid and PEI were each diluted in 50 ml saline and mixed, after which the volume of the complex was made to 1 ml with Optimem (Invitrogen) and used to transfect cells seeded in sixwell multidishes. Transfection complexes were removed after 3 h, and cells were washed with PBS. Fresh growth medium was added and the cells were grown for a further 48 h before being assayed for luciferase activity.
Luciferase reporter assay
Cells transfected with pVR1223 were washed twice with PBS and lysed using 300 ml/well of reporter lysis buffer (RLB) (Promega, Madison, WI, USA). Cell lysates were treated as described by Promega using their Luciferase assay system. Relative light units were measured using a Turner TD 20/20 Luminometer, after a 3 s delay, over a 10 s integration period. Luciferase activity was standardized to the protein content of each sample determined using the BioRad protein assay (BioRad, Hemel Hempstead, UK). Protein concentrations were calculated from a BSA standard curve and luciferase activity was expressed as RLU/mg protein or RLU/mg protein.
Intranasal delivery of luciferase reporter gene transfection complexes to BALB/c mice
For luciferase reporter gene delivery, female BALB/c (Charles River Laboratories, Margate, UK) and BALB/c nude mice (6-8 weeks old) (Harlan UK Ltd, Bicester UK) were anaesthetized using the inhalational anaesthetic methoxyflurane (Metofane, Mallinckrodt Veterinary, Mundelein, IL, USA). For intranasal delivery, mice were held at an angle of 451 in a supine position with pressure applied to the lower mandible to immobilize the tongue and thus prevent swallowing. Lipoplexes contained 20 mg pVR1223 complexed for 15 min at room temperature with 100 mg of DCChol/DOPE in a final volume of 200 ml HBS. PEI-DNA transfections were performed at an N/P ratio of 10:1, 20 mg of plasmid was mixed with the required amount of each PEI in 150 mM NaCl in a 200 ml volume followed by incubation at room temperature for 15 min. Lipoplexes and PEI-DNA complexes, in a total volume of 200 ml, were added to the nasal planum of the mouse using a pipetman (P200 Gilson), the respiratory pattern of the mice resulted in prompt inhalation of the transfection complex, generally within approximately 10 s. Mice were monitored during recovery to consciousness.
Processing of lung, nasal and tracheal tissue
Mice were killed at different time points after transfection by cervical dislocation. A small cut was made in the left atrium, and the circulation perfused with 20 ml of cold PBS via the right ventricle. Nasal epithelium was dissected from each animal and homogenized manually in a 1.5 ml microfuge tube with 150 ml RLB, and placed on dry ice. Each trachea was dissected from each animal and placed in a 1.5 ml microfuge tube with 150 ml RLB, and placed on dry ice. Thawed trachea were cut longitudinally and the tracheal epithelia scraped into RLB and both tracheal carcass and epithelia placed on dry ice. Lungs were dissected from each animal and transferred to 200 ml RLB, mechanically homogenized (Pro 200 homogenizer, Pro Scientific Inc., CT, USA) and then placed on dry ice. Frozen samples were thawed and cell debris pelleted by a 12 000 g spin for 10 min at 41C. Luciferase reporter assays were performed on all samples. were anaesthetized using the inhalational anaesthetic methoxyflurane and intranasal delivery was performed as above. CF-null mice were transfected with either a hCFTR expression plasmid (pT10CFTR2) 31 or empty plasmid vector (pT10) complexed with linear 22 kDa PEI at an N/P ratio of 10:1. At 12 h post-transfection, trachea were mounted in Ussing chambers. Tracheas were dissected to remove the larynx and opened longitudinally by cutting through the centre of the cartilage rings. Each trachea was mounted in an Ussing chamber (window size 2.3 mm 2 ), bathed on both the apical and basolateral surfaces with 20 ml Kreb's Henseleit solution (KHS pH 7.4; 118 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl 2 , 1.2 mM KH 2 PO 4 , 25 mM NaHCO 3 and 11.1 mM glucose) at 371C and bubbled with 95% O 2 /5% CO 2 . Transepithelial potentials were measured, via KHS-filled electrodes with 3 M KCL/1.5% agarose plugs, by calomel cells connected to a WPI DVC-1000 voltage/current clamp (World Precision Instruments Fl. USA). The SCC across the epithelium was measured by voltage clamping the tissue at zero potential. Genistein activation of CFTRmediated Cl À secretion in the murine trachea was investigated as previously described. 32 
Statistical analysis of data
Results were compared by either a paired Student's ttest, using SigmaPlot (Statistical Solutions Ltd, Cork, Ireland), or a two-tailed Mann-Whitney Wilcoxon rank sum test using Minitab (Minitab Inc., State College, PA, USA) when the data set did not show a normal distribution. The power of the study, the probability of getting a significant result, concerning the genistein response (data shown in Figure 5 ) is 0.21. One-way ANOVA analysis was also used to test statistical differences between experimental groups.
